Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
Age
50–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and Female patients 50 years old or older Symptomatic peripheral artery disease
You may not be if
Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
Patients with known bleeding disorders
Patients with a history of intracranial bleed
Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
